University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Department of Dermatology, University of Pittsburgh, UPMC North Hills Dermatology, 9000 Brooktree Rd Suite 200, Wexford, PA, 15090, USA.
Am J Clin Dermatol. 2018 Aug;19(4):559-584. doi: 10.1007/s40257-018-0350-0.
Nail psoriasis (NP) and nail lichen planus (NLP) can be limiting, stigmatizing and difficult to treat. Dermatologists commonly treat psoriasis and lichen planus but when associated onychodystrophy is present or is an isolated finding, some develop apprehension. The goal of this review is to develop therapeutic ladders to be used as a guide for the management of NP and NLP in everyday clinical practice. Evidence-based therapies for NP are robust and range from topical treatments to conventional systemic therapies (i.e., methotrexate, cyclosporine), new oral agents (i.e., apremilast and tofacitinib), and biologics. The literature for treatment of NLP is severely limited, with therapy mainly consisting of topical, intralesional, or systemic corticosteroids or methotrexate.
甲银屑病(NP)和甲扁平苔藓(NLP)可能会造成限制、污名化并难以治疗。皮肤科医生通常会治疗银屑病和扁平苔藓,但当存在甲营养不良或为孤立性发现时,一些医生会感到担忧。本综述的目的是制定治疗阶梯,作为日常临床实践中治疗 NP 和 NLP 的指南。NP 的循证治疗方法是可靠的,范围从局部治疗到传统的全身治疗(例如,甲氨蝶呤、环孢素)、新型口服药物(例如,阿普司特和托法替布)和生物制剂。治疗 NLP 的文献严重受限,治疗主要包括局部、皮损内或全身皮质类固醇或甲氨蝶呤。